Oncocorner

Webinar

Dec
2025

00
CET

Tumour sites CME application in progress

Anti-HER2 therapies: biological mechanisms and toxicity management

This webinar explores the biological foundations and clinical management of anti-HER2 therapies in breast cancer. Experts will discuss the molecular mechanisms underlying HER2-targeted treatments and their role in improving patient outcomes, while also addressing the challenges of managing therapy-related toxicities. The session aims to provide a comprehensive and practical overview for clinicians and researchers involved in the care of patients with HER2-positive breast cancer.

ACKNOWLEDGMENTS

Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.

This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).

Speakers

Discussant

Alexandru Eniu

Consultant Medical Oncologist at Clinique de Genolier, Genolier, Switzerland

Expert

Tal Sella

Breast Oncologist at Sheba Medical Center, Ramat Gan, Israel

Expert

Paola Zagami

New Drugs and Early Drug Development for Innovative Therapies Dept. at European Institute of Oncology, Milan, Italy